首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1734254

甲狀旁腺功能低下症市場-全球與區域分析-分析與預測（2025-2035）

Hypoparathyroidism Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035

出版日期: 2025年05月28日 | 出版商:

BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄圖表

全球甲狀旁腺功能低下症市場目前正處於其生命週期的成長階段。

人們對疾病的認知不斷提高以及診斷技術的進步導致市場早期診斷和治療的增加。包括新型副甲狀腺素療法在內的新治療方法的開發正在擴大治療甲狀旁腺功能低下症的治療選擇，進一步推動市場成長。此外，人們對罕見疾病和個人化醫療的日益關注，加上有利的監管支持，正在刺激對研發的投資，從而帶來創新治療方法的推出。

隨著新興市場醫療保健服務的改善和治療選擇的日益廣泛，預計市場將繼續擴大。然而，治療費用上漲和某些地區認知度低等挑戰可能會影響成長速度。總體而言，由於治療方法的不斷進步和全球影響力的不斷擴大，全球甲狀旁腺功能低下症市場預計將持續成長。

影響

預計在 2025-2035 年預測期內，對甲狀旁腺功能低下症治療的需求不斷增加將支持全球甲狀旁腺功能低下症市場的成長。
由於標靶治療藥物的開發、認知和診斷的提高以及臨床管道的不斷擴大，全球甲狀旁腺功能低下症市場預計將顯著成長。

近期動態

監管活動：2025 年 2 月，Specialised Therapeutics 的 YORVIPATH核准用於治療成人慢性甲狀旁腺功能低下症。
監管行動 2024 年 8 月，FDA核准了一種每日一次的副甲狀腺素前驅藥物，用於治療成人甲狀旁腺功能低下症。
夥伴關係：2024 年 7 月，製藥科學部門 Pendopharm 與 scendis Pharma 簽署了獨家分銷協議，將治療甲狀旁腺功能低下症的藥物 TransCon PTH（paropegteriparatide）引入加拿大市場。

需求－促進因素與限制因素

驅動程式

甲狀旁腺功能低下症功能低下症盛行率不斷上升
診斷技術的認知提升與進步

限制因素

醫療費用高昂

產品/創新策略：全球甲狀旁腺功能低下症市場的創新以增強患者護理的治療方案的進步為中心。市場的主要參與企業如 Specialised Therapeutics 和 Ascendis Pharma 都參與開發甲狀旁腺功能低下症的治療方法。

競爭策略：領先的市場參與者不斷透過創新治療方法更新產品系列以保持競爭力。它對主要參與者進行了詳細的競爭基準化分析，並提供了這些公司在產品平臺和創新方面的比較情況的見解。透過這種基準測試，讀者可以清楚地了解市場格局和主要企業的地位。此外，包括夥伴關係、協議和聯盟在內的綜合競爭策略可協助讀者發現市場中尚未開發的商機。

主要市場參與企業及競爭格局

公司簡介是根據從主要專家收集的資訊以及透過分析公司覆蓋範圍、產品系列和市場滲透率來選擇的。

本報告研究了全球甲狀旁腺功能低下症市場，並概述了市場以及區域趨勢和公司概況。

The global hypoparathyroidism market is currently in the growth stage of its lifecycle. With increasing awareness of the condition and advancements in diagnostic technologies, the market is witnessing a rise in early diagnosis and treatment initiation. The development of new therapies, including novel parathyroid hormone treatments, has expanded the treatment options available for managing hypoparathyroidism, further fueling market growth. Additionally, the growing focus on rare diseases and personalized medicine, coupled with favorable regulatory support, has spurred investment in research and development, leading to the introduction of innovative therapies.

As healthcare access improves in emerging markets and treatment options become more widely available, the market is expected to continue its expansion. However, challenges such as high treatment costs and limited awareness in certain regions may impact the pace of growth. Overall, the global hypoparathyroidism market is positioned for continued growth with increasing therapeutic advancements and expanding global reach.

Impact

Increasing demand for hypoparathyroidism therapies is anticipated to support the growth of the global hypoparathyroidism market during the forecast period 2025-2035.
The global hypoparathyroidism market is expected to grow at a significant rate due to developments in targeted therapies, rising awareness and diagnosis, and a growing clinical pipeline.

Recent Developments

Regulatory Activities: In February 2025, Therapeutic Goods Administration approved Specialised Therapeutics' YORVIPATH for the treatment of chronic hypoparathyroidism in adults.
Regulatory Activities: In August 2024, the FDA approved a once-daily parathyroid hormone prodrug for the treatment of adults with hypoparathyroidism.
Partnerships: In July 2024, Pharmascience unit Pendopharm entered into an exclusive distribution agreement with Ascendis Pharma to bring the hypoparathyroidism treatment TransCon PTH (palopegteriparatide) to the Canadian market.

Demand - Drivers and Limitations

Drivers:

Increasing Prevalence of Hypoparathyroidism
Rising Awareness and Advancements in Diagnostic Technologies

Limitations:

High Treatment Costs

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Innovations in the global hypoparathyroidism market are centered on advancing treatment options to enhance patient care. Key players in the market, such as Specialised Therapeutics and Ascendis Pharma, have been involved in the development of therapies for hypoparathyroidism.

Competitive Strategy: Enterprises led by market leaders continually update their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product pipeline and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolios, and market penetration.

Some of the prominent names established in this market are:

Ascendis Pharma
AstraZeneca
Bridgebio
Entera Bio Ltd.
MBX Biosciences, Inc.
Specialised Therapeutics
Visen Pharmaceuticals (Shanghai) Co., Ltd.

Scope of Study

1. Global Hypoparathyroidism Market Overview

1.1 Industry Outlook
- 1.1.1 Market Overview and Ecosystem
- 1.1.2 Market Trend
- 1.1.3 Epidemiological Analysis of Hypoparathyroidism
  - 1.1.3.1 By Region
    - 1.1.3.1.1 U.S.
    - 1.1.3.1.2 EU5
    - 1.1.3.1.3 Rest-of-the-World
- 1.1.4 Clinical Trials
  - 1.1.4.1 By Phase
  - 1.1.4.2 By Sponsor Type
- 1.1.5 Regulatory Landscape / Compliance
  - 1.1.5.1 Legal Requirement and Framework in the U.S.
  - 1.1.5.2 Legal Requirement and Framework in the E.U.
  - 1.1.5.3 Legal Requirement and Framework in Japan
  - 1.1.5.4 Legal Requirement and Framework in Rest-of-the-World
1.2 Market Dynamics
- 1.2.1 Impact Analysis
- 1.2.2 Market Drivers
- 1.2.3 Market Restraints
- 1.2.4 Market Opportunities

2. Global Hypoparathyroidism Market, By Region, $Million, 2023-2035

2.1 U.S.
- 2.1.1 Market Dynamics
- 2.1.2 Market Size and Forecast
2.2 Europe
- 2.2.1 Market Dynamics
- 2.2.2 Market Size and Forecast
  - 2.2.2.1 Europe Hypoparathyroidism Market (by Country)
    - 2.2.2.1.1 U.K.
    - 2.2.2.1.2 Germany
    - 2.2.2.1.3 France
    - 2.2.2.1.4 Italy
    - 2.2.2.1.5 Spain
2.3 Rest-of-the-World
- 2.3.1 Market Dynamics
- 2.3.2 Market Size and Forecast

3. Global Hypoparathyroidism Market - Competitive Benchmarking and Company Profiles

3.1 Competitive Landscape
- 3.1.1 Key Strategies and Developments by Company
  - 3.1.1.1 Funding Activities
  - 3.1.1.2 Mergers and Acquisitions
  - 3.1.1.3 Regulatory Approvals
  - 3.1.1.4 Partnerships, Collaborations and Business Expansions
- 3.1.2 Key Developments Analysis
3.2 Company Profiles
- 3.2.1 Ascendis Pharma
  - 3.2.1.1 Company Overview
  - 3.2.1.2 Product Portfolio
  - 3.2.1.3 Target Customers/End Users
  - 3.2.1.4 Analyst View
- 3.2.2 AstraZeneca
  - 3.2.2.1 Company Overview
  - 3.2.2.2 Product Portfolio
  - 3.2.2.3 Target Customers/End Users
  - 3.2.2.4 Analyst View
- 3.2.3 Bridgebio
  - 3.2.3.1 Company Overview
  - 3.2.3.2 Product Portfolio
  - 3.2.3.3 Target Customers/End Users
  - 3.2.3.4 Analyst View
- 3.2.4 MBX Biosciences, Inc.
  - 3.2.4.1 Company Overview
  - 3.2.4.2 Product Portfolio
  - 3.2.4.3 Target Customers/End Users
  - 3.2.4.4 Analyst View
- 3.2.5 Entera Bio Ltd.
  - 3.2.5.1 Company Overview
  - 3.2.5.2 Product Portfolio
  - 3.2.5.3 Target Customers/End Users
  - 3.2.5.4 Analyst View
- 3.2.6 Specialised Therapeutics
  - 3.2.6.1 Company Overview
  - 3.2.6.2 Product Portfolio
  - 3.2.6.3 Target Customers/End Users
  - 3.2.6.4 Analyst View
- 3.2.7 Visen Pharmaceuticals (Shanghai) Co., Ltd.
  - 3.2.7.1 Company Overview
  - 3.2.7.2 Product Portfolio
  - 3.2.7.3 Target Customers/End Users
  - 3.2.7.4 Analyst View

4. Research Methodology

簡介目錄圖表

List of Figures

Figure: Global Hypoparathyroidism Market, Market Overview
Figure: Global Hypoparathyroidism Market, Epidemiological Analysis, U.S.
Figure: Global Hypoparathyroidism Market Coverage
Figure: Global Hypoparathyroidism Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Hypoparathyroidism Market, Competitive Landscape, January 2022-April 2025